A detailed history of Price T Rowe Associates Inc transactions in Gossamer Bio, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 2,891,005 shares of GOSS stock, worth $2.78 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,891,005
Previous 3,695,227 21.76%
Holding current value
$2.78 Million
Previous $3.37 Million 1.19%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$0.8 - $1.51 $643,377 - $1.21 Million
-804,222 Reduced 21.76%
2,891,005 $3.41 Million
Q4 2023

Feb 14, 2024

BUY
$0.48 - $1.08 $1.77 Million - $3.99 Million
3,695,227 New
3,695,227 $3.37 Million
Q2 2023

Aug 14, 2023

BUY
$0.98 - $1.53 $239,267 - $373,549
244,150 Added 22.72%
1,318,680 $1.58 Million
Q1 2023

May 15, 2023

SELL
$0.96 - $2.92 $224,905 - $684,088
-234,277 Reduced 17.9%
1,074,530 $1.36 Million
Q4 2022

Feb 14, 2023

BUY
$1.74 - $12.87 $2.26 Million - $16.7 Million
1,298,783 Added 12956.73%
1,308,807 $2.84 Million
Q3 2022

Nov 14, 2022

BUY
$7.21 - $14.88 $72,273 - $149,157
10,024 New
10,024 $121,000

Others Institutions Holding GOSS

About Gossamer Bio, Inc.


  • Ticker GOSS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 93,954,000
  • Market Cap $90.2M
  • Description
  • Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony...
More about GOSS
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.